• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为 BSL-0 环境设计的超高效慢病毒载体可消除载体的转移。

Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization.

机构信息

Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Transplant Diagnostics, Thermo Fisher Scientific, Canoga Park, CA, 91303, USA.

出版信息

Gene Ther. 2018 Oct;25(7):454-472. doi: 10.1038/s41434-018-0039-2. Epub 2018 Sep 6.

DOI:10.1038/s41434-018-0039-2
PMID:30190607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6478381/
Abstract

Lentiviral vector mobilization following HIV-1 infection of vector-transduced cells poses biosafety risks to vector-treated patients and their communities. The self-inactivating (SIN) vector design has reduced, however, not abolished mobilization of integrated vector genomes. Furthermore, an earlier study demonstrated the ability of the major product of reverse transcription, a circular SIN HIV-1 vector comprising a single- long terminal repeat (LTR) to support production of high vector titers. Here, we demonstrate that configuring the internal vector expression cassette in opposite orientation to the LTRs abolishes mobilization of SIN vectors. This additional SIN mechanism is in part premised on induction of host PKR response to double-stranded RNAs comprised of mRNAs transcribed from cryptic transcription initiation sites around 3'SIN-LTR's and the vector internal promoter. As anticipated, PKR response following transfection of opposite orientation vectors, negatively affects their titers. Importantly, shRNA-mediated knockdown of PKR rendered titers of SIN HIV-1 vectors comprising opposite orientation expression cassettes comparable to titers of conventional SIN vectors. High-titer vectors carrying an expression cassette in opposite orientation to the LTRs efficiently delivered and maintained high levels of transgene expression in mouse livers. This study establishes opposite orientation expression cassettes as an additional PKR-dependent SIN mechanism that abolishes vector mobilization from integrated and episomal SIN lentiviral vectors.

摘要

HIV-1 感染转导细胞后的慢病毒载体动员给接受载体治疗的患者及其社区带来了生物安全风险。然而,自我失活(SIN)载体设计减少了,但并未消除整合载体基因组的动员。此外,先前的一项研究表明,逆转录的主要产物,即包含单个长末端重复序列(LTR)的圆形 SIN HIV-1 载体,能够支持高载体滴度的产生。在这里,我们证明了将内部载体表达盒配置为与 LTRs 相反的方向会消除 SIN 载体的动员。这种额外的 SIN 机制部分基于诱导宿主 PKR 对来自 3'SIN-LTR 和载体内部启动子周围隐秘转录起始位点的 mRNA 转录产生的双链 RNA 的反应。正如预期的那样,反方向载体转染后 PKR 反应会对其滴度产生负面影响。重要的是,PKR 的 shRNA 介导敲低使包含反方向表达盒的 SIN HIV-1 载体的滴度与传统 SIN 载体的滴度相当。携带与 LTR 相反方向的表达盒的高滴度载体能够有效地递送至小鼠肝脏,并维持高水平的转基因表达。这项研究确立了反方向表达盒作为一种额外的 PKR 依赖性 SIN 机制,可消除整合和附加型 SIN 慢病毒载体的载体动员。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/af604a9d8f7d/nihms-1023454-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/59e675a4d8a5/nihms-1023454-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/fbcfbac0a6da/nihms-1023454-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/36541247fd53/nihms-1023454-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/99ed745a80d3/nihms-1023454-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/0047725e7fe2/nihms-1023454-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/dd8097c99b63/nihms-1023454-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/af604a9d8f7d/nihms-1023454-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/59e675a4d8a5/nihms-1023454-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/fbcfbac0a6da/nihms-1023454-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/36541247fd53/nihms-1023454-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/99ed745a80d3/nihms-1023454-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/0047725e7fe2/nihms-1023454-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/dd8097c99b63/nihms-1023454-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fe3/6478381/af604a9d8f7d/nihms-1023454-f0007.jpg

相似文献

1
Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization.为 BSL-0 环境设计的超高效慢病毒载体可消除载体的转移。
Gene Ther. 2018 Oct;25(7):454-472. doi: 10.1038/s41434-018-0039-2. Epub 2018 Sep 6.
2
Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration.整合型自我失活慢病毒载体产生能够进行包装和整合的全长基因组转录本。
J Virol. 2004 Aug;78(16):8421-36. doi: 10.1128/JVI.78.16.8421-8436.2004.
3
3' self-inactivating long terminal repeat inserts for the modulation of transgene expression from lentiviral vectors.用于调节慢病毒载体转基因表达的3' 自失活长末端重复序列插入片段
Hum Gene Ther Methods. 2012 Apr;23(2):84-97. doi: 10.1089/hgtb.2011.154. Epub 2012 Mar 28.
4
Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.靶向人类免疫缺陷病毒1型多个高度保守RNA序列的慢病毒小干扰RNA
Gene Ther. 2005 Jul;12(14):1133-44. doi: 10.1038/sj.gt.3302509.
5
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.表达由RNA聚合酶III介导的抗HIV RNA的慢病毒载体对HIV-1感染的抑制作用
Mol Ther. 2003 Aug;8(2):196-206. doi: 10.1016/s1525-0016(03)00165-5.
6
Development of a self-inactivating lentivirus vector.一种自失活慢病毒载体的开发。
J Virol. 1998 Oct;72(10):8150-7. doi: 10.1128/JVI.72.10.8150-8157.1998.
7
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.γ逆转录病毒载体和慢病毒自我失活(SIN)载体在造血细胞中表达O6-甲基鸟嘌呤-DNA甲基转移酶的效力相同。
Mol Ther. 2006 Feb;13(2):391-400. doi: 10.1016/j.ymthe.2005.08.012. Epub 2005 Oct 12.
8
Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.表达抗HIV-1基因的慢病毒载体作为HIV-1感染的辅助治疗手段。
Curr HIV Res. 2004 Apr;2(2):185-91. doi: 10.2174/1570162043484906.
9
Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors.整合型自我失活慢病毒载体的转录激活与机制
J Virol. 2005 Jul;79(13):8410-21. doi: 10.1128/JVI.79.13.8410-8421.2005.
10
Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.携带抗HIV短发夹RNA的慢病毒载体:问题与解决方案
J Gene Med. 2007 Sep;9(9):743-50. doi: 10.1002/jgm.1078.

引用本文的文献

1
Engineering safe anti-CD19-CD28ζ CAR T cells with CD8a hinge domain in serum-free media for adoptive immunotherapy.在无血清培养基中构建具有CD8a铰链区的安全抗CD19-CD28ζ嵌合抗原受体T细胞用于过继性免疫治疗
Front Immunol. 2025 May 9;16:1545549. doi: 10.3389/fimmu.2025.1545549. eCollection 2025.
2
Engineered packaging cell line for the enhanced production of baboon-enveloped retroviral vectors.用于增强狒包膜逆转录病毒载体生产的工程包装细胞系。
Mol Ther Nucleic Acids. 2024 Nov 13;35(4):102389. doi: 10.1016/j.omtn.2024.102389. eCollection 2024 Dec 10.
3
Genetic alteration of SJ293TS cells and modification of serum-free media enhances lentiviral vector production.

本文引用的文献

1
FDA approves hereditary blindness gene therapy.美国食品药品监督管理局批准遗传性失明基因疗法。
Nat Biotechnol. 2018 Jan 10;36(1):6. doi: 10.1038/nbt0118-6a.
2
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.逆转录病毒和慢病毒基因修饰 T 细胞产品的安全性分析及输注 HIV 和肿瘤患者。
Mol Ther. 2018 Jan 3;26(1):269-279. doi: 10.1016/j.ymthe.2017.10.012. Epub 2017 Oct 20.
3
Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned.造血干细胞基因治疗:进展与经验教训。
SJ293TS细胞的基因改造和无血清培养基的改良可提高慢病毒载体的产量。
Mol Ther Methods Clin Dev. 2024 May 21;32(2):101270. doi: 10.1016/j.omtm.2024.101270. eCollection 2024 Jun 13.
4
A novel high-titer, bifunctional lentiviral vector for autologous hematopoietic stem cell gene therapy of sickle cell disease.一种用于镰状细胞病自体造血干细胞基因治疗的新型高滴度双功能慢病毒载体。
Mol Ther Methods Clin Dev. 2024 Apr 24;32(2):101254. doi: 10.1016/j.omtm.2024.101254. eCollection 2024 Jun 13.
5
CRISPR library screening to develop HEK293-derived cell lines with improved lentiviral vector titers.利用CRISPR文库筛选开发具有更高慢病毒载体滴度的HEK293衍生细胞系。
Front Genome Ed. 2023 Jul 13;5:1218328. doi: 10.3389/fgeed.2023.1218328. eCollection 2023.
6
Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy.用于癌症免疫治疗的人肿瘤靶向细胞毒性肥大细胞
Front Oncol. 2022 Apr 22;12:871390. doi: 10.3389/fonc.2022.871390. eCollection 2022.
7
Improved lentiviral vector titers from a multi-gene knockout packaging line.来自多基因敲除包装细胞系的改进型慢病毒载体滴度。
Mol Ther Oncolytics. 2021 Nov 20;23:582-592. doi: 10.1016/j.omto.2021.11.012. eCollection 2021 Dec 17.
8
Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization.基于猿猴免疫缺陷病毒的整合酶缺陷型慢病毒载体用于免疫接种的安全性和效率改进
Mol Ther Methods Clin Dev. 2021 Oct 1;23:263-275. doi: 10.1016/j.omtm.2021.09.011. eCollection 2021 Dec 10.
9
β-Globin Lentiviral Vectors Have Reduced Titers due to Incomplete Vector RNA Genomes and Lowered Virion Production.β-珠蛋白慢病毒载体由于不完全的载体 RNA 基因组和降低的病毒粒子产量而导致滴度降低。
Stem Cell Reports. 2021 Jan 12;16(1):198-211. doi: 10.1016/j.stemcr.2020.10.007. Epub 2020 Nov 12.
10
The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology.《旧与新:非整合慢病毒载体技术的前景》。
Viruses. 2020 Sep 29;12(10):1103. doi: 10.3390/v12101103.
Cell Stem Cell. 2017 Nov 2;21(5):574-590. doi: 10.1016/j.stem.2017.10.010.
4
First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.首例人类应用靶向树突状细胞的慢病毒载体表达 NY-ESO-1、LV305 治疗难治性转移性滑膜肉瘤患者,诱导深度、持久应答。
J Immunother. 2017 Oct;40(8):302-306. doi: 10.1097/CJI.0000000000000183.
5
First approval in sight for Novartis' CAR-T therapy after panel vote.在专家小组投票后,诺华的CAR-T疗法有望首次获批。
Nat Biotechnol. 2017 Aug 8;35(8):691-693. doi: 10.1038/nbt0817-691.
6
FDA panel recommends approval of first gene therapy in US.美国食品药品监督管理局专家小组建议批准美国首个基因疗法。
BMJ. 2017 Jul 14;358:j3443. doi: 10.1136/bmj.j3443.
7
Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I.溶酶体贮积症的基因治疗:异染性脑白质营养不良和黏多糖贮积症 I 的最新进展。
J Inherit Metab Dis. 2017 Jul;40(4):543-554. doi: 10.1007/s10545-017-0052-4. Epub 2017 May 30.
8
Toward Personalized Gene Therapy: Characterizing the Host Genetic Control of Lentiviral-Vector-Mediated Hepatic Gene Delivery.迈向个性化基因治疗:表征慢病毒载体介导的肝脏基因递送的宿主遗传控制
Mol Ther Methods Clin Dev. 2017 Apr 5;5:83-92. doi: 10.1016/j.omtm.2017.03.009. eCollection 2017 Jun 16.
9
Gene Therapy 2017: Progress and Future Directions.《2017年基因治疗:进展与未来方向》
Clin Transl Sci. 2017 Jul;10(4):242-248. doi: 10.1111/cts.12466. Epub 2017 May 23.
10
The sense behind retroviral anti-sense transcription.逆转录病毒反义转录背后的意义。
Virol J. 2017 Jan 14;14(1):9. doi: 10.1186/s12985-016-0667-3.